Affiliation:
1. Department of Pharmaceutical Science Hirosaki University Graduate School of Medicine Hirosaki Aomori Japan
2. Department of Pharmacy Hirosaki Central Hospital Hirosaki Aomori Japan
3. Department of Pharmacy Hirosaki University Hospital Hirosaki Aomori Japan
4. Department of Innovation Center for Health Promotion Hirosaki University Graduate School of Medicine Hirosaki Aomori Japan
5. Department of Social Medicine Hirosaki University Graduate School of Medicine Hirosaki Aomori Japan
Abstract
AbstractIn this study, we investigated the impact of single nucleotide polymorphisms in solute carrier (SLC) transporters, that is, SLC22A7 c.1586 + 206A > G, SLC22A2 c.808G > T, SLC22A3 c.1233G > A, SLC47A1 c.922‐158G > A, and SLC47A2 c.‐130G > A, on serum creatinine (SCr) concentrations. This cross‐sectional study included residents who participated as volunteers in a health promotion study. Lifestyle data, blood chemical analysis data, and SLC gene polymorphism information were collected from each participant. Univariate analyses were carried out to determine differences between groups and correlations in SCr. Stepwise multiple regression analysis was performed to confirm the independence of factors that were significantly different in the univariate analyses. In multiple regression analyses, muscle mass, serum cystatin C concentrations, body fat percentage, serum albumin concentrations, and SLC47A2 c.‐130G/G had the highest contribution to SCr concentrations, in that order (standardized regression coefficients = .505, .332, −.234, .123, and .084, respectively). The final model explained 72.2% of the variability in SCr concentrations. The SLC47A2 c.‐130G > A polymorphism may affect creatinine dynamics in the proximal tubules. Further studies are needed to determine the effects of SLC transporter gene polymorphisms on SCr concentrations in patients with various diseases in real‐world clinical settings.
Subject
General Pharmacology, Toxicology and Pharmaceutics,Neurology